Bottom line
DLRHX vs FTXH: the short answer
DLRHX (Nomura Healthcare Fund) and FTXH (First Trust Nasdaq Pharmaceuticals ETF) are both mutual funds.
But DLRHX is far broader, holding 108 positions to 51 for FTXH, so beyond the top names it adds exposure FTXH doesn't have.
FTXH is cheaper at 0.6% vs 1.46% — a difference of $86 a year per $10,000 invested.
Over five years, DLRHX returned +7.2% a year vs +6.5% for FTXH.
Updated Nov 19, 2026
DLRHX vs FTXH side by side
| DLRHX | FTXH | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Voya | First Trust |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.46% | 0.6% |
| Annual cost per $10k | $146 | $60 |
| 10-yr cost on $10k (prospectus) | $1,797 | — |
| Max front load | 0% | None |
| 12b-1 fee | 0.5% | 0% |
| 1-yr return | +21.8% | +24.0% |
| 5-yr return (annualized) | +7.2% | +6.5% |
| 10-yr return (annualized) | +9.9% | — |
| Best quarter | — | +18.3% |
| Worst quarter | — | −17.4% |
| Net assets (fund) | $750.2M | $36.2M |
| Number of holdings | 108 | 51 |
| Portfolio turnover | 4% | 35% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
13 of DLRHX's top 25 holdings also appear in FTXH's top 25.
| Holding | DLRHX | FTXH |
|---|---|---|
| Abbvie Inc | 4.19% | 7.39% |
| Eli Lilly & Company | 4.16% | 7.77% |
| Regeneron Pharmaceuticals Inc | 3.91% | 2.72% |
| Pfizer Inc | 3.84% | 2.97% |
| Merck & Company Inc | 3.68% | 7.07% |
| Gilead Sciences Inc | 3.54% | 2.89% |
| Viatris Inc | 2.48% | 3.62% |
| Halozyme Therapeutics Inc | 2.30% | 1.21% |
| Amgen Inc | 2.27% | 3.18% |
| Illumina Inc | 2.11% | 1.98% |
| Alkermes Plc | 1.82% | 1.35% |
| Vertex Pharmaceuticals Inc | 1.66% | 3.41% |
| Neurocrine Biosciences Inc | 1.57% | 1.37% |
Source: SEC Form N-PORT
DLRHX top 10
- Ucb Sa — 5.19%
- Abbvie Inc — 4.19%
- Eli Lilly & Company — 4.16%
- Regeneron Pharmaceuticals Inc — 3.91%
- Unitedhealth Group Inc — 3.88%
- Pfizer Inc — 3.84%
- Merck & Company Inc — 3.68%
- Gilead Sciences Inc — 3.54%
- Astrazeneca Plc — 3.27%
- Elevance Health Inc — 3.25%
FTXH top 10
- Eli Lilly & Company — 7.77%
- Abbvie Inc — 7.39%
- Merck & Company Inc — 7.07%
- Johnson & Johnson — 6.96%
- Bristol-myers Squibb Company — 6.29%
- Biogen Inc — 3.84%
- Viatris Inc — 3.62%
- Cardinal Health Inc — 3.53%
- Vertex Pharmaceuticals Inc — 3.41%
- Amgen Inc — 3.18%
FAQ
What is the difference between DLRHX and FTXH?
Which is cheaper, DLRHX or FTXH?
Should I own both DLRHX and FTXH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.